New drug T-DXd could outperform standard chemo in HER2+ breast cancer
NCT ID NCT05900206
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial compares the experimental drug trastuzumab deruxtecan (T-DXd) to standard chemotherapy given before surgery for HER2-positive breast cancer. About 370 participants will receive either T-DXd or standard treatment for three cycles, then further treatment is chosen based on the tumor's molecular type. The main goal is to see if T-DXd leads to a higher rate of complete tumor disappearance at surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- trastuzumab deruxtecan (T-DXd, Enhertu)
- What this could lead to
- If successful, this could show that T-DXd is more effective than standard chemo at shrinking HER2-positive breast tumors before surgery, potentially leading to a new treatment option.
- What could go wrong
- This is a phase 2 trial with 370 participants, so results are still early. T-DXd may not prove superior, and side effects like lung inflammation or heart issues are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karolinska University Hospital
RECRUITINGStockholm, 17164, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Norrlands University Hospital
NOT_YET_RECRUITINGUmeå, 90185, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sankt Gorans Hospital
NOT_YET_RECRUITINGStockholm, 11219, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Skåne University Hospital
NOT_YET_RECRUITINGMalmö, 21428, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stockholm Southern Hospital
NOT_YET_RECRUITINGStockholm, 11861, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Uppsala University Hospital
NOT_YET_RECRUITINGUppsala, 75185, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Örebro University Hospital
NOT_YET_RECRUITINGÖrebro, 70185, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A dab of gel on the breathing tube might spare surgery patients a sore throat — a trial puts it to the test.
- Can a deeper nerve block ease pain after breast surgery?
- Does breast cancer radiation harm a key immune gland? a study investigates
- A web program may ease the emotional toll of chemotherapy hair loss
- Can a new drug outsmart resistant breast cancer?